Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02344290 · ClinicalTrials.gov registry record · Phase 3
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 7,769
- Enrollment target
NCT02344290 is a Phase 3 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 7,769 participants.
The verdict
NCT02344290, a Phase 3 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7,769 participants
- Enrollment target
Study Summary
People with HIV are at risk for cardiovascular disease (CVD). This study evaluated the use of pitavastatin to reduce the risk of CVD in adults with HIV on antiretroviral therapy (ART). The REPRIEVE trial consisted of two parallel identical protocols: * REPRIEVE (A5332) was funded by the NHLBI, with additional infrastructure support provided by the NIAID, and was conducted in U.S and select international sites (approximately 120 sites in 11 countries). * REPRIEVE (EU5332) was co-sponsored by NEAT ID and MGH, and was conducted at 13 sites in Spain.
Interventions
- DRUG Placebo
- DRUG Pitavastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,769 participants |
| Start Date | 2015-03-26 |
| Est. Completion | 2023-08-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02344290
The ClinicalTrials.gov registry entry for NCT02344290 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 7,769 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02344290 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02344290 about?
NCT02344290 is a clinical study titled "Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults". People with HIV are at risk for cardiovascular disease (CVD). This study evaluated the use of pitavastatin to reduce the risk of CVD in adults with HIV on antiretroviral therapy (ART). The REPRIEVE trial consisted of two parallel identical protocols: * REPRIEVE (A5332) was funded by the NHLBI, wit...
What is the current status of trial NCT02344290?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7,769 participants. The study started on 2015-03-26. Estimated completion is 2023-08-21.
What interventions are being tested in trial NCT02344290?
The interventions under investigation include: Placebo (DRUG), Pitavastatin (DRUG).
Who is sponsoring clinical trial NCT02344290?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.